Previous 10 | Next 10 |
Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q2 2024 Bank of China Ltd. ADR (BACHY) is expected to report for Q2 2024 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.11 for Q3 2023 Soho House & Co Inc. Class A (SHCO) is expected to report...
2023-11-09 13:01:38 ET Summary Madrigal Pharmaceuticals is more than 100% higher than a year ago, though the stock has been grinding constantly lower from it's high-water mark in late-April, sitting some 55% below that level. The company completed a $500 million stock offering to ...
HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...
Akero Therapeutics Inc. (AKRO) is expected to report $-0.69 for Q3 2023
2023-10-26 01:30:02 ET Summary 89bio shows promise in NASH therapeutics, backed by robust Phase 2b trials of its drug pegozafermin. Financially stable with a significant cash runway, but a sharp YoY increase in operating expenses without a partnership to offset some costs is a con...
2023-10-20 15:00:13 ET More on the markets S&P 500 Will Likely Underperform And 5% Money Markets Are NOT The Answer Equities Climbing A Wall Of Worry (Technical Analysis) SPY: Short-Term Bounce Testing The Downtrends (Technical Analysis) Here is why you s...
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present virtually ...
2023-10-12 16:38:06 ET Shares of Akero Therapeutics (NASDAQ: AKRO) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence . The healthcare stock closed last week at $50.33, then hit a 52-week low of $14.0...
2023-10-10 15:58:09 ET More on Akero Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data Akero Therapeutics: An Assessment Biggest stock movers today: Coherent, Truist Financial, Akero Therapeutics and more Akero plummets after m...
2023-10-10 13:28:32 ET Summary Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Despite the setback, AKRO stock is still trading higher than it was in September 2022, before another Phase 2 study succeeded...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...